The involvement of stromal derived factor 1α in homing and progression of multiple myeloma in the 5TMM model

Haematologica

Volumn 91, Issue 5, 2006, Pages 605-612

  Menu, Eline ^a   Asosingh, Kewal ^b   Indraccolo, Stefano ^c   De Raeve, Hendrik ^d   Van Riet, Ivan ^a   Van Valckenborgh, Els ^a   Vande Broek, Isabelle ^a   Fujii, Nobutaka ^e   Tamamura, Hirokazu ^f   Van Camp, Ben ^a   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e KYOTO UNIVERSITY   (Japan)

^f TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chemokines; Myeloma; SDf1

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER GROWTH; CELL ADHESION; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; KILLER CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANIMALS; BONE MARROW CELLS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CHEMOKINES, CXC; CHEMOTAXIS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PEPTIDES; RECEPTORS, CXCR4; STROMAL CELLS;

EID: 33744467387     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991;77:2688-93.
2. Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994;84:2269-77.
3. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-20.
4. Van Riet I, Van Camp B. The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 1993;9:441-52.
5. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-6.
6. Tanaka T, Bai Z, Srinoulprasert Y, Yang B, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005;96:317-22.
7. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 1994;91:2305-9.
8. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-5.
9. Erratum in: Nature 1996;384:288.
10. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-9.
11. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-42.
12. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-9.
13. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003;170:1136-40.
14. Pelletier AJ, van der Laan LJ, Hildbrand P, Siani MA, Thompson DA, Dawson PE, et al. Presentation of chemokine SDF-1 α by fibronectin mediates directed migration of T cells. Blood 2000;96:2682-90.
15. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-20.
16. +) cells: evidence for an autocrine/paracrine mechanism. Blood 2002;99:1117-29.
17. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G, et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001;194:45-56.
18. Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003;17:203-10.
19. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-51.
20. Parmo-Cabanas M, Bartolome RA, Wright N, Hidalgo A, Drager AM, Teixido J. Integrin α4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004;294:571-80.
21. Hideshima, T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther 2002;1:539-44.
22. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. Faseb J 2004;18:1240-2.
23. Kijima, T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11.
24. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003;100:13513-8.
25. Scotton, CJ, Wilson JE, Scott K. Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-8.
26. Zeelenberg IS, Ruuls-Van Stalle E, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;63:3833-9.
27. Radl J, De Glopper E, Schuit HRE. Zurcher C. Idiopathic paraproteinemia II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 1979;122:609-13.
28. Vanderkerken K, De Greef C, Asosingh K, Arteta B, De Veerman M, Vande Broek I, et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 2000;82:953-9.
29. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76:451-60.
30. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series, a useful in vivo mouse model of human multiple myeloma. The Hematol J 2000;1:351-6.
31. Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 2004;33:111-9.
32. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003;550:79-83.
33. Piovan, E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, Trentin L, et al. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood 2004;105:931-9.
34. Leber T, Balkwill F. Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 1997;249:24-8.
35. Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, Noel A, et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 2002;86:796-802.
36. Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004;18:976-82.
37. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
38. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005;65:465-72.
39. Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human MM cells: a close association with disease activity and survival. Submitted.
40. Pellegrino A, Ria R, Di Pietro G, Cirulli T, Sunco G, Pennisi A, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 2005;129:248-56.
41. Wright N, Hidalgo A, Rodriguez-Frade JM, Soriano SF, Mellado M, Parmo-Cabanas M, et al. The chemokine stromal cell-derived factor-1α modulates α4β7 integrin-mediated lymphocyte adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin. J Immunol 2002;168:5268-77.
42. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling cooperate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005;24:4462-71.
43. nd scientific meeting on bone disease in MM 2001; UKMF.
44. Samara GJ, Lawrence DM, Chiarelli CJ, Valentino MD, Lyubsky S, Zucker S, et al. CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 2004;214:231-41.
45. Yu X, Collin-Osdoby P, Osdoby P. SDF-1 increases recruitment of osteoclast precursors by upregulation of matrix metalloproteinase-9 activity. Connect Tissue Res 2003;44 Suppl 1:79-84.
46. Tamamura H, Hiramatsu K, Mizumoto M, Ueda S, Kusano S, Terakubo S, et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem 2003;1:3663-9.
47. Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 2004;90:1076-83.
48. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 2005;105:3793-801.
49. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B, et al. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-90.
50. Menu E, Jernberg Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cycloligand PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 200;107:655-60.
51. Asosingh K, Gunthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 2001;61:2862-5.
52. Martin SK, Farrugia AN, Diamond P, Gronthos S, Horvath N, Gamble J, et al. Myeloma plasma cell derived SDF1α and RANKL act synergistically to stimulate neo angiogenesis. The Hematology J 2005;90:sP911.
53. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.